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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an evidence based-
cellular immunotherapy for hematological malignancies. Immune reactions not only
promote graft-versus-tumor effects that kill hematological malignant cells but also graft-
versus-host disease (GVHD) that is the primary complication characterized by systemic
organ damages consisting of T-cells and antigen presenting cells (APCs) activation. GVHD
has long been recognized as an immunological reaction that requires an
immunosuppressive treatment targeting immune cells. However immune suppression
cannot always prevent GVHD or effectively treat it once it has developed. Recent studies
using high-throughput sequencing technology investigated the impact of microbial flora
on GVHD and provided profound insights of the mechanism of GVHD other than immune
cells. Allo-HSCT affects the intestinal microbiota and microbiome-metabolome axis that
can alter intestinal homeostasis and the severity of experimental GVHD. This axis can
potentially be manipulated via dietary intervention or metabolites produced by intestinal
bacteria affected post-allo-HSCT. In this review, we discuss the mechanism of
experimental GVHD regulation by the complex microbial community-metabolites-host
tissue axis. Furthermore, we summarize the major findings of microbiome-based
immunotherapeutic approaches that protect tissues from experimental GVHD.
Understanding the complex relationships between gut microbiota-metabolites-host
tissues axis provides crucial insight into the pathogenesis of GVHD and advances the
development of new therapeutic approaches.
Keywords: graft-versus-host disease, microbial metabolite, dysbiosis, microbiota, allogeneic stem
cell transplantationINTRODUCTION
Hematological malignancies, such as leukemia, lead to high mortality, especially in the elderly.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an immune therapy that has
become widely used for the treatment of life-threatening hematological malignancies and congenic
immune deficiencies (1). However, many complications following allo-HSCT occur due to immune-
related reactions, the most challenging and serious of which is graft-versus-host disease (GVHD) (2).org August 2021 | Volume 12 | Article 7032981
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tissues (3). After T-cells activation and migration to GVHD
target organs, such as the lung, gut, liver and skin, cytotoxic
T-cells and helper T-cells attack target cells in these target
organs. Once GVHD develops, recipients require additional
immunosuppressive therapies using steroids in addition to
GVHD preventive immunosuppressants consisting of
calcineurin inhibitors. However, GVHD is frequently refractory
to standard steroid therapy and has a dismal prognosis, with only
5–30% overall survival (4). In steroid-refractory GVHD, novel
treatment approaches include the use of anti-thymocyte
globulin, extracorporeal photopheresis, mesenchymal stromal
cells, mycophenolate mofetil, everolimus, sirolimus, etanercept,
infliximab, and ruxolitinib (5). Intensified immunosuppressive
therapies for aggravated GVHD suppress immune reactions and
permit bacterial translocation from injured intestinal epithelium
cells; this leads to subsequent systemic infections that increase
the release of pathogen-associated molecular patterns (PAMPs)
and damage associated molecular patterns (DAMPs). This
negative feedback loop can result in fatal GVHD. In addition,
excessive immunosuppression increases malignancy relapse after
HSCT. Thus, immunosuppressive therapies are limited.
Current focus has been shifted to the target tissues, the third
player in GVHD, in addition to APCs and T-cells (3). The role of
tissue-intrinsic factors that might contribute to the regulation of
GVHD severity has been largely overlooked. Tissue-specific
programs contribute to target tissue resilience, repair, and
regeneration and mitigate the severity of GVHD without
altering the load or function of alloreactive immune cells (6).
In this context, the gastro-intestinal (GI) tract has close
interactions with the microbiota, and recent genomic microbial
analyses have revealed intricate connections between the
microbiota and various diseases. Particularly, in GVHD,
disturbance of microbial composition, that is, dysbiosis, is
strongly associated with poor outcomes after allo-HSCT (7).
However, whether a causal relationship exists remains unclear.
In this review, we focus on the connection among gut
microbiota, microbial metabolites and intestinal environment
that affect GVHD. We also discuss the recent findings on
microbiome-based immunotherapeutics that affect or mitigate
GVHD and enumerate the emerging strategies for the regulation
of dysbiosis and microbial metabolites in the regulation
of GVHD.
Gut Microbiota and Intestinal
Epithelial Cells
A close relationship between microbiota and human health has
been investigated. Microbiota refers to the community
comprising trillions of microorganisms, including bacteria,
fungi, and viruses, that symbiotically colonize the human body,
most members of which reside in the gut and are largely
nonpathogenic anaerobic commensal bacteria (8). This balance
is finely tuned in the gastrointestinal (GI) tract and influenced by
the environment, diet, and host factors, including host
physiology (9). The mammalian GI tract is a relatively hypoxic
tissue and has a steep oxygen (O2) gradient between the O2-richFrontiers in Immunology | www.frontiersin.org 2lamina propria and the gut lumen, which is dominated by
anaerobic organisms (10). Aerobic and facultative anaerobic
bacteria have been suggested to consume oxygen in the distal
intestine and maintain hypoxia in the lumen, leading to the
colonization by strict anaerobes and the production of short-
chain fatty acids (SCFAs) (11). Complex dietary carbohydrates
(fiber) are broken down by these bacteria into digested
fermentation products, that are absorbed by the host and
utilized for host nutrition, immune development, and niche
protection against enteric pathogens (12–19). Members of
Clostridia and Bacteroidia are the obligate anaerobic bacteria
dominating in the colon and capably digest any carbohydrate
complex into fermentation products (20, 21). Facultative
anaerobic bacteria such as Proteobacteria are not specialized in
consuming fiber, and rather interfere with host nutrition by
changing metabolites to carbon dioxide under oxygen (22, 23).
Fermented metabolite effects have been observed in a neonatal
mouse model with Clostridia species colonization that protected
neonatal mice form virulent pathogens (24). Intestinal epithelial
cells (IECs) are continuously renewed from the crypts where
intestinal stem cells (ISCs) are located. ISCs divide and
differentiate into transit-amplifying (TA) cells, IECs,
enteroendocrine cells and goblet cells (25). In contrast to TA
and ISCs that utilize glucose to obtain energy through glycolysis,
IECs produce energy viamitochondrial b-oxidation of fatty acids
and oxidative phosphorylation, both of which require oxygen
(26, 27). Butyrate is a favored metabolic substrate that maintains
epithelial energy homeostasis (26). Despite low O2 conditions,
high butyrate levels result in the downregulation of the glycolytic
pathway and the upregulation of mitochondrial respiration (28).
This drastic change of energy production was triggered with the
expression of peroxisome proliferator-activated receptor-g
(PPAR-g), which is a nuclear receptor synthesized in
differentiated IECs of rodents and humans (29). The energy
metabolism in IECs consumes a high amount of oxygen, leading
to low oxygen pressure in the lumen (30). This oxygen
consumption in IECs permits epithelial hypoxia and helps to
maintain anaerobic bacterial flora in the intestinal lumen (31). The
hypoxic environment enables obligate anaerobic bacteria that
produce carbohydrate metabolites to colonize and provide
benefits to the host. Epithelial metabolism of SCFA is a primary
determinant of ‘‘physiologic hypoxia’’ in the mucosa with O2
consumption and hypoxia-inducible factor (HIF) stabilization
that promotes barrier function (32). Therefore, IECs are
uniquely adapted to this hypoxic environment, and cells
programmed by “physiological hypoxia” have been shown to
tonally regulate barrier function (33). These mechanisms
indicated that IECs influence the shaping of beneficial
microbiota, and those microbiotas bring metabolic profits to the
host. In this process IECs play a central role in maintaining gut
homeostasis (Figure 1).
The IECs and gut microbiota function in two distinct
manners: protection against ingested pathogens and induction
of tolerance to beneficial commensals. The intestinal immune
system matured by microbiota stimulates the mucosa-producing
cells (i.e., Paneth cells and goblet cells) to secrete antimicrobialAugust 2021 | Volume 12 | Article 703298
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barriers, such as the mucus layer and tight junctions that
regulates the relationship between the microbiota and the host
(34). Germ-free mice have distinct gut features, such as altered
intestinal morphology and slower turnover of IECs than
conventional mice (35). After exposure to exogenous
commensal bacteria, germ-free mice responded to intestinal
bacteria. Four days post-exposure, innate immune responses
and structural changes in the intestinal epithelial crypts were
observed, i.e., increased TNF-a and interferon-g (IFN-g)
expression and upregulation of MHC class I molecules (35).
IECs in SPF mice also expressed MHC class II molecules that
were deficient in germ free mice (36). Under the inflammatory
status such as GVHD, gut microbiome stimulated IL-12
production from myeloid cells, resulting in increased
expression of MHC class II on IECs through IFN-g produced
from lamina propria lymphocytes. In summary, the intestinal
environment shapes and maintains the microbiota. Also,Frontiers in Immunology | www.frontiersin.org 3microbiota and those metabolites play important roles on both
the function and metabolism in IECs.
Mechanism of Dysbiosis in Hematopoietic
Cell Transplantation
Associations between the microbiota and HSCT outcomes have
been extensively studied in the 1970s (37). According to these early
studies, specific pathogen-freemice treated with antibiotics or germ-
free mice that received HSCT developed less severe GVHD than
their respective controls. These attempts were validated in HSCT
patients with gut decontamination by antibiotics (38). Recently,
broad-spectrum antibiotics that target anaerobic pathobionts have
been revealed to increase GVHD-related mortality in mouse and
human (39). Therefore, some antibiotics that perturb microbial
composition were unsuitable for patients in HSCT settings. The
microbial compositions of various anaerobic commensal intestinal
bacterial species were robustly disturbed and reduced due to chemo/
radiotherapy, antibiotics, or HSCT itself in patients (40). DecreasedFIGURE 1 | Suggestive mechanisms of epithelial metabolism and gut microbiota in HSCT. (A) Before HSCT, gut microbiota, especially obligate anaerobic bacteria,
ferment fiber from diet into metabolites, such as SCFAs. Intestinal epithelial cells (IECs) metabolize short chain fatty acids (SCFAs) and consume oxygen to produce
energy. High oxygen consumption limits the oxygen diffusion into the lumen and maintains hypoxia in the lumen. Hypoxic condition enables obligate anaerobes to
keep growth. The scale bar indicates oxygen (O2) levels, usually between 3% to 10% in normal intestines. (B) During HSCT, conditioning treatments including
irradiation and high-dose chemotherapy damages IECs, and injured IEC decreases oxygen consumption. Decreased dietary fiber and antibiotics treatments during
HSCT disrupt microbiota composition, especially reduce obligate anaerobes, and deplete the fermentative products. Reduced SCFAs limit oxygen consumption to
produce energy in IECs and permit oxygen diffusion into the gut lumen. Elevated oxygen concentration drives an expansion of facultative anaerobic bacteria and
might lead to a contraction of obligate anaerobes. In GVHD, allogeneic T-cells promote IEC injuries and require antibiotics treatments, that could enhance and
maintain dysbiosis in the gut.August 2021 | Volume 12 | Article 703298
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spp., were reported as risk factors that resulted in poor outcomes
after HSCT (41). The mono-domination of Enterococcus was
significantly associated with severe GVHD and treatment related
mortality (TRM) in mice and human studies (42). These studies
indicate the causative role of Enterococcus in the pathogenesis of
GVHD. However, the mechanism of dysbiosis post-HSCT remains
unclear (7, 43). Before and after HSCT, patients receive various
interventions that are likely to contribute to the microbial dysbiosis.
Importantly, in a mouse model of acute GVHD exposure to a
GVHD-associated gut microbiome pre- and/or post- HSCT
accelerated GVHD development and severity demonstrating the
complex relationship between GVHD and microbiota (44). These
factors could affect the intestinal microbial composition (Figure 1).
Radiotherapy
As a part of allo-HSCT, systemic irradiation is frequently used to
kill fast-dividing leukemia/lymphoma cells and host myeloid cells/
lymphocytes. However, radiation causes intestinal damage, and
the potential correlation between dysbiosis and radiation-induced
damage has been revealed (45, 46). Radiation induces oxidative
stress via the generation of reactive oxygen species (ROS),
including hydroxyl radical (OH), superoxide anion (O2−), and
hydrogen peroxide (H2O2), resulting in the activation of
cyclooxygenases (COX), nitric oxide synthases, lipoxygenases,
and nicotinamide adenine dinucleotide phosphate oxidases.
These products of oxidative stress cause DNA damage,
inflammation, and apoptosis in IECs and affect the gut
microbiota composition through homeostatic disturbances (45).
The relationship between radiation enteritis and dysbiosis was
observed in patients receiving radiotherapy. Relatively high
abundances of Proteobacteria and Gammaproteobacteria,
characterized by increased oxidative stress resistance in
Enterobacteriaceae, Phyllobacteriaceae, and Beijerinckiaceae, and
low abundance of Bacteroides with decreased Bacteroidaceae
and Ruminococcaceae that were sensitive to oxidative stress,
were detected (46). Recently, a multi-omics study reported
Lachnospiraceae and Enterococcaceae as radioprotective
microbes and elevated SCFA levels due to irradiation damage in
mice receiving irradiation (47). Bifidobacterium can utilize
indigestive fibers, such as fructose oligosaccharides (FOS),
inulin-type fructans (ITF), and xylo-oligosaccharides (XOS), and
cross-feed with lactate-converting bacteria and butyrate-
producing bacteria, i.e., Eubacterium hallii and Anaerostipes
caccae (48). Although Bifidobacterium cannot produce butyrate,
it is associated with increased abundance of butyrogenic bacteria
in a cross-feeding manner (49). Moreover, Eubacterium hallii L2-7
and Anaerostipes caccae L1-92 could not grow in starch but grew
upon co-culture with Bifidobacterium adolescentis L2-32 to
produce butyrate (50). Collectively, the abundance of specific
bacterial species is reduced and eventually lost post irradiation
before allo-HSCT.
Chemotherapy
Elaborating the purpose of repeated intensive chemotherapy before
allo-HSCT reduces microbiota diversity in both human and mice
and leads to the expansion of Escherichia Coli and EnterococcusFrontiers in Immunology | www.frontiersin.org 4spp (51). During allo-HSCT, disrupted gut microbial composition
and diversity, including decreased abundances in Bifidobacterium,
butyrate-producing Faecalibacterium and Lachnospiraceae, were
highly associated with transplant-related mortality (7).
Methotrexate treatments caused a significant reduction in the
number of Bifidobacterium and Lactobacillus species and
Escherichia coli in children with leukemia (52). Etoposide exhibits
broad bacterial inhibitory activity that changes microbial
composition in vitro (53). In leukemia patient data, it is suggested
that chemotherapy induces dysbiosis (51). Healthy volunteers in the
Human Microbiome Project (HMP) and patients with acute
myeloid leukemia in the pre-induction phase showed no
significant differences in terms of microbial diversity. After
neutrophil recovery, microbial diversity in the leukemia group
was significantly decreased and this dysbiosis was associated with
an increased risk of infections and the use of broad-spectrum
antibiotics. Within 3 months of anti-anaerobic antibiotic
administrations including carbapenem and piperacillin-
tazobactam, a significant reduction in microbial diversity was also
observed before allo-HSCT in the recipients (54). Multiple intensive
chemotherapies for acute leukemia patients also disrupt the
microbial composition and promote the outgrowth of pathogenic
bacteria such as Enterococcus (55). Another study demonstrated
that pre-transplant microbial composition differed from the healthy
controls due to decreased abundances of beneficial bacteria,
Bifidobacterium, Faecalibacterium, and Lachnospiraceae (56).
Overall, these findings suggest that pre-transplant microbe
disruption increased HSCT comorbidity. However, the
mechanisms of dysbiosis onset and the disruption of the
microbiota by chemotherapy are still unknown. Furthermore,
these studies could not separate the effects of HSCT from those of
antibiotics (39).
Antibiotics
Chemotherapies for hematological malignancies cause high-
grade neutropenia and require systemic antibiotic
administration to prevent or treat life-threatening bacterial
infections. The influence of antibiotics on the microbial
composition should be accounted for. Recent microbiome
studies have observed undesirable consequences in dysbiosis,
including antibiotic resistance, pathogenic bacteria dominance,
transient or profound loss of microbial diversity, increased
susceptibility to infection, and the risk of recurrent infections,
after antibiotic usage in cancer patients (57). However,
immunocompromised individuals are at high risk of intestinal
infections, which are difficult to treat without using broad-
spectrum antibiotics (58). As reported by various studies,
oxygen-tolerant species, Enterococcus, Enterobacteriaceae,
Klebsiella spp., and Viridans streptococci, are most commonly
translocated from damaged intestinal mucosal barrier due to
chemotherapy, irradiation, and antibiotics to the bloodstream
(59). Prophylactic antibiotics, such as quinolones, are usually
utilized to prevent infections in patients receiving HSCT. Once
they develop fever or infections, broad-spectrum antibiotics,
such as piperacillin-tazobactam or meropenem, are prescribed
(60). Compared to pre-transplant conditions, decreased
Firmicutes and Actinobacteria and increased Bacteroides andAugust 2021 | Volume 12 | Article 703298
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(61). Notably, the use of rifaximin could preserve gut beneficial
commensals and improve patient outcomes (62). HSCT patients
receiving rifaximin showed significantly lower TRM, prolonged
OS, and a tendency for low acute GI-GVHD rates than historical
controls. These observations remained unknown even in patients
who developed neutropenic fever and received systemic
antibiotics without an increase in sepsis rates or pathogenic
bacterial colonization. Efforts to investigate and identify the
antibiotics that could spare microbial compositions to reduce
acute GI-GVHD and adverse outcomes have been attempted
(63). A study in patients from Canada also assessed the effects of
prophylactic and therapeutic antibiotic administration before
day 0 of HSCT (64). The antibiotic-receiving group had a
significantly higher incidence of acute GVHD (aGVHD) and
shorter survival. The early administration of systemic antibiotics
before engraftment was also associated with low 3-IS levels and
reduced Clostridia abundance in the intestines, leading to higher
TRM rates than those without systemic antibiotics before
engraftment (65). These studies suggest the association of
antibiotic usage affecting microbial diversity and GVHD-
related outcomes. Piperacillin-tazobactam and meropenem,
known as broad-spectrum antibiotics that are also effective
against anaerobic bacteria, caused decreased microbiome
diversity during transplantation in mice and humans (39, 66).
In mouse models, these antibiotics lead to microbial injury with
loss of colonic mucosa and intestinal barrier function caused by
mucin-degrading bacteria, Akkermansia muciniphila (39). The
load of anti-anaerobic antibiotic usage was correlated with a
significant decrease in anti-inflammatory Clostridia (AIC)
abundance and aGVHD in pediatric HSCT patients (67). This
decrease was recovered by the administration of AIC after
clindamycin treatment and improved survival in a mouse
GVHD model (67, 68). Among the broad-spectrum antibiotics
administered during HSCT, meropenem showed significantly
decreased microbial diversity and a higher rate of GI-HVHD
onset compared to no antibiotics, but cefepime did not change
the diversity with a trend of increased GI-GVHD onset rates
(69). In a pediatric study, anti-anaerobic antibiotics resulted in a
significant decrease of SCFA-producing bacteria, especially
butyrate-producing commensals and butyrate levels in the
luminal content. These patients developed aGVHD with low
butyrate levels in stools compared to patients without GVHD
(70). Single bacterial taxa dominated by Enterococcus and
Streptococcus was observed in two-thirds of patients with
bloodstream infections around the time of engraftment (71).
The significant elevation of enterococcus expansion was
increased by metronidazole administration, and VRE
bacteremia was significantly increased (3-fold and 9-fold,
respectively). Integrating these studies, although antibiotic
prophylaxis and systemic administration clearly improved
TRM, especially infection-related mortality, we need
comprehensive choices of antibiotic usage around HSCT
periods comparing weights of disease status, donor sources,
history of antibiotic usage, status of microbial injuries, and
other risk factors.Frontiers in Immunology | www.frontiersin.org 5METABOLIC CHANGES IN
COLONOCYTES
IECs might control the homeostasis that shapes the microbiota
to be beneficial (72). Dysbiosis that caused increased abundance
of facultative anaerobic bacteria, is observed in the population
consuming a high-fat Western-style diet, patients with
inflammatory bowel disease, colorectal cancer, irritable bowel
syndrome or necrotizing enterocolitis (73–80). It has been
proposed that shift of microbial community from obligate to
facultative anaerobic bacteria that can utilize oxygen could be
associated with a disruption in aerobiosis, a concept “oxygen
hypothesis” in mouse inflammatory bowel disease models (81,
82). This microbial shift might be associated with the colonocyte
metabolic dysfunction (31). Disruption of gut homeostasis was
observed in antibiotic treatment that altered IECs metabolism by
depleting microbes that produce SCFAs in a mouse colitis model
(19, 32). Decreased SCFAs increases the inflammatory tone of
the colonic mucosa in mice (83). In the animal model, elevation
of inflammatory signals shifts the metabolism in IECs toward an
aerobic glycolysis, reduced oxygen consumption and high
glucose consumption and high lactate release (84). These
metabolic changes result in a loss of epithelial hypoxia (32).
Increased oxygen concentration elevates the amount of oxygen
in mucosal surface, therefore drives an expansion of facultative
anaerobic bacteria (85). These associations between metabolic
condition in IECs and dysbiosis are not validated in GVHD
settings and the future investigations are required.
Butyrate and Lactase Pathway
Recent evidence has suggested that dysbiosis post allo-HSCT are
related to the butyrate and lactase pathways (86). Butyrate is
produced from non-digestible fiber by anaerobic bacterial
species, including those belonging to Firmicutes, Lachnospiraceae,
Ruminococcaceae, Lactobacillus spp., and Bifidobacterium
adolescentis. Other bacterial phyla including Bacteroides,
Actinobacteria, Fusobacteria, and Proteobacteria are also potent
butyrate producers (87). These bacteria are sensitive to oxidative
stress caused by chemotherapy and irradiation administered
before HSCT, leading to their reduced abundances and the
subsequent decrease in butyrate volume in the lumen. At the
intestinal level, butyrate is a protective molecule against
inflammation, a histone deacetylase inhibitor, and an energy
source for epithelial cells (68, 88). Therefore, decreased butyrate
concentration led to GVHD augmentation due to the disturbance
of intestinal homeostasis and the activation of inflammatory
environment in the intestine. Another mechanism that causes
dysbiosis post-HSCT in GVHD patients involves the domination
of the lactic acid bacteria (LAB) Enterococcus faecium in the
gut (42). In GVHD patients, metabolism of lactose and galactose
is impaired by the overexpression of enzymes and lactases (89).
In adults, lactase is mainly produced by the microbiota,
including species belonging to Actinobacteria, Proteobacteria,
and Firmicutes (90). Each LAB has distinct enzymatic
characteristics and behaves differently depending on each
feature. LABs are mainly gram-positive, acid-tolerant bacteriaAugust 2021 | Volume 12 | Article 703298
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Pediococcus, Lactococcus, and Oenococcus (91). They produce
lactase that catalyzes the conversion of carbohydrates (such as
lactose, glucose, sucrose, and galactose) into lactic acid and
facilitates lactose absorption (92, 93). The reduction in the
number of commensal LAB mediated by conditioning
chemotherapy, radiotherapy, and antibiotics post-HSCT leads
to high lactose concentrations. For example, Enterococci are a
part of the normal intestinal microbiota and can cause clinical
problems. Particularly, Enterococcus faecium and some
Enterococcus faecalis encode genes related to lactose and
galactose metabolism (42). Enterococcus faecium metabolizes
citrate and lactose to produce lactate, whereas E. faecalis can
produce superoxide and H2O2 that damage colonic epithelial
cells (94, 95). These enterococci require lactose for growth
in vitro (lactose auxotroph) and are associated with intestinal
inflammation and damages (96). These pathways were observed
following the expansion of Enterococci early after HSCT in
patients with the increased risk of HSCT-related mortality (43).
Butyrate and lactase pathway could be a target for treating
dysbiosis in HSCT. The analysis of these pathways for TRM
post HSCT has been reviewed in detail previously (89).MICROBIAL METABOLITES IN GVHD
The intestinal microbiota produces various microbial
metabolites that maintain intestinal homeostasis (97, 98).
These metabolites affect both IECs and immune cells in the
intestine to maintain intestinal barrier function and host
immune responses (97). Changes in microbial composition led
to poor HSCT outcomes; however, to date, there is no conclusive
evidence that changes in gut microbial metabolites affect GVHD
severity and TRM.
Short-Chain Fatty Acids
SCFAs, including acetate, butyrate, and propionate, are products
of fermented carbohydrates by anaerobic commensal bacteria
Clostridia spp (99). SCFAs have multipotent effects on both IECs
and intestinal immune cells (Figure 2). Particularly, butyrate
serves as an energy source for IECs as demonstrated by reduced
autophagy in SPF mice compared to germ-free mice (26). In
addition, SCFAs preserve the intestinal mucosal barrier by
supporting goblet cells via upregulating mucin-related genes.
The supplementation of SCFA-producing bacteria in germ-free
rats showed goblet cell maturation (100–102). SCFAs also
maintain the IEC barrier integrity that prevents pathogenic
bacterial translocation (103). Furthermore, they play an
important role in innate immunity, neutrophils, mononuclear
cells, macrophages, and dendritic cells and act as histone
deacetylase (HDAC) inhibitors with anti-inflammatory effects
(99, 101, 102). SCFAs also affect Tregs to promote differentiation
and anti-inflammatory responses in a mouse colitis model (17).
Moreover, anti-inflammatory IL-10 production from Foxp3-
positive Tregs via HDAC inhibition was observed in germ-free
mice with SCFA supplementation (18, 104). A high-fiber dietFrontiers in Immunology | www.frontiersin.org 6and acetate activated the inflammasome and promoted IL-18
production, which modulated epithelial repair in murine colitis
model (105). Butyrate also increased IL-18 expression in IECs
and IL-10 expression in DCs and macrophages, thereby inducing
Treg differentiation in mice (106). Recently, a metabolomic
analysis of murine intestine and contents revealed a significant
reduction in butyrate in the IECs from GVHD mice and that the
supplementation of butyrate or butyrate-producing bacteria
ameliorated acute GVHD via HDAC inhibition and gut
integrity maintenance (68, 107). Butyrate and propionate
directly protected IECs via inflammasome activation through
SCFA-sensing receptors in murine GVHD model (108). In
humans, small clinical studies have found that the high fecal
butyrate and propionate concentrations are decreased in acute
GVHD patients and that high circulating butyrate and
propionate concentrations in the blood are associated with
protection from chronic GVHD (70, 107). Other studies
examined fecal SCFA concentrations after allo-HSCT and
reported that the concentrations of butyrate and other SCFAs
correlate with the abundance of butyrate-producing bacteria in
the intestinal microbiota and are higher in patients with
resistance to lower tract respiratory infections (109). However,
the effect of SCFAs on GVHD needs to be examined in patients
after allogeneic HSCT.
During HSCT, recipients have problems that limit oral intake
due to mucositis and receive total parenteral nutrition (TPN). In
both mice and humans, TPN skewed immune responses to pro-
inflammatory conditions (110, 111). Positive nutritional support
using sucrose improved hematopoietic recovery compared to
antibiotic-treated recipients in mice (112). These studies overall
suggest the potential of specific diet elements (prebiotics) during
HSCT. Resistant carbohydrate supplementation can stimulate
SCFA production in the intestine as the microbiota can
metabolize resistant starch (RS) (113). Among various
formulations of RS, that derived from potatoes was identified
as a potent candidate for increasing fecal butyrate levels in
healthy adults (114). Remarkably, RS administration to allo-
recipients around HSCT periods was demonstrated as feasible
and safe and lead to increased fecal butyrate levels concomitant
with high RS degrading and butyrate-producing bacteria in a
human pilot study (115). However, the clinical data on the effects
of prebiotics in acute GVHD are limited. Inulin and fructo-
oligosaccharides have potential as prebiotics in inflammatory
bowel disease patients as they led to the expansion of intestinal
microbial diversity (116, 117). To determine the exact role of
nutritional modulation using RS in the microbiome and
metabolites affecting GVHD severity, clinical trials are
currently ongoing (www.clinicaltrials.gov: NCT02763033). A
clinical trial that evaluating the safety and tolerability of fructo-
oligosaccharides in HSCT patients (NCT02805075) is
also underway.
Bile Acids
Bile acid is a microbial metabolite affected by intestinal microbial
composition (118). Primary bile acids are generated in the liver via
cholesterol catabolism. These primary bile acids are conjugated to
glycine and taurine in the final step of synthesis and are secretedAugust 2021 | Volume 12 | Article 703298
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transported to the liver (119). Secondary bile acids are converted by
microbial enzymes from primary bile acids that were not absorbed.
Two main receptors, the nuclear farnesoid X receptor (FXR) and G
protein-coupled bile acid receptor 1 (GPBAR1; TGR5), are known.
FXR-deficient mice showed abnormal IEC functions, thus causing
bacterial translocation from the intestine (120). TGR5 signaling
from bile acids activates macrophages and inhibits the production of
pro-inflammatory cytokines TNF-a and IL-1 by inhibiting the
nuclear factor-kB (121). Dietary fat-induced taurocholic acid in
IL-10-deficient mice enhanced colitis in mice by altering the
intestinal microbiota and pro-inflammatory Th1 responses (75).Frontiers in Immunology | www.frontiersin.org 7While bile acids are not well absorbed in patients with intestinal
GVHD and serum sample analysis of allo-HSCT patients revealed
altered bile acid concentrations, ursodeoxycholic acid, a secondary
bile acid, is clinically used to reduce hepatic complications and
GVHD (122–124). In a recent study, tauroursodeoxycholic acid,
another bile acid, reduced the experimental murine GVHD severity
(124). Tauroursodeoxycholic acid decreased antigen presentation
on IECs, and the apoptosis of IECs without affecting the
microbial composition and graft-versus-leukemia/lymphoma
(GVL) effects. Taurine is a metabolite related to bile acids that
stimulates the Nod-like receptor family protein domain
containing 6 (NLRP6). NLRP6 stimulation leads to innateFIGURE 2 | Mechanisms of short chain fatty acids on intestinal epithelial cells in the pathophysiology of gastrointestinal GVHD. In the normal condition, short chain
fatty acids (SCFAs) that are metabolites from microbial fermentation of dietary fibers, protect intestinal epithelial cells (IECs) in at least 3ways. (i) G-protein-coupled
receptors (GPRs) on IECs, especially GPR43, sensor SCFAs and signal ERK phosphorylation leading to subsequent NLRP3 inflammasome activation, that promotes
IEC integrity. In graft-versus-host disease (GVHD), decreases of GPRs on IECs and reduced SCFAs from dysbiosis diminish intracellular signaling via ERK-NLRP3
pathway, resulting in IEC damages. (ii) One of SCFAs, butyrate acts as a histone deacetylase inhibitor, and increases various target gene expressions, including anti-
apoptotic BCL-B and the junctional protein JAM (junctional adhesion molecule). These gene expressions result in decreased IEC apoptosis and enhanced junctional
integrity, leading to IEC protection. In GVHD, reduced butyrate fails to protect histones from deacetylation and decreased target gene expression, resulting in low
resistance against allogeneic T-cell injuries. (iii) Butyrate activates peroxisome proliferator-activated receptor-g (PPAR-g) signaling in IECs and promotes mitochondrial
ß-oxidation that produce enough amount of energy to protect and maintain IECs from cellular damages. In GVHD, reduced butyrate might not activate PPAR-g,
resulting in mitochondrial dysfunction for energy production that are inappropriate for IEC protection against allogeneic T-cell injuries. This mechanism is studied in
inflammatory bowel disease but not validated in GVHD. Further investigations are required.August 2021 | Volume 12 | Article 703298
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inflammasome-related cytokine production, and promotion of
intestinal epithelial integrity (125). Taurine has been reported to
stimulate NLRP6 in IECs and augment GVHD severity in mice
(126). These data suggest that bile acids are promising microbial
metabolites that can be used to reduce GVHD severity.
Aryl Hydrocarbon Receptor Ligands
Aryl hydrocarbon receptor (AhR) modulates mucosal immune
responses via the ligand-activated transcription factor. AhR
ligands are produced from the endogenous and exogenous
pathway in the body. In an endogenous pathway, they are
produced through intestinal microbial metabolism. Lactobacilli,
Fusobacterium, Bacteroides and Enterococcus faecalis convert the
amino acid, tryptophan, into AhR ligands, such as indole-3-
aldehyde and its derivatives (127, 128). In a human GVHD
cohort, preserved microbial diversity and Clostridia spp were
correlated with 3-IS concentrations in the urine (129). In serum
metabolic comparisons of HLA identical donors and recipients,
indolepropionate that was derived from microbiota, was a
smaller amount in recipients at the time of GVHD onset (123).
3-IS is also known as a uremic toxin associated with adverse
outcomes in renal disease patients. In this setting, monocytes
respond to 3-IS through AhR pathway and release TNF-a,
resulting in the pro-inflammatory condition with endothelial
damage leading to cardiovascular disease (130). AhR ligands
maintain IEC barrier functions. AhR-deficient mice have
decreased levels of anti-microbial peptides and intestinal
epithelial lymphocytes and reduced IEC turnover with altered
microbial composition in mice (131). AhR also regulates innate
immunity in the intestine by expanding the IL-22-producing
retinoic acid receptor-related orphan receptor gt (RORgt)+
group 3 innate lymphoid cells (ILC3s) (132), thereby affecting
adaptive immunity (133). In murine GVHD models, a few
investigations were reported. Recipient mice that exposed to
lethal irradiation or chemotherapeutic conditioning regimens
had lower urinary concentrations of 3-IS (134). The
supplementation of indole-3 carboxaldehyde, an indole
derivative, ameliorated gut epithelial damages with reduced
inflammatory cytokines, leading to improved survival. In
murine GVHD models, AhR-deficient T-cells ameliorated
GVHD through the expansion of peripherally induced Tregs
(135). AhR ligand levels were decreased in patients at the onset of
GVHD (123). However, the mechanism by which the AhR
pathway affects GVHD in mice and humans remains unknown.
Tyrosine Derived Metabolites
Tyrosine derived metabolites are produced from tyrosine
fermentation by microbiota in the large intestine (136).
Tyrosine is one of the non-essential amino acids that is
involved in catecholamine synthesis (137). The function of
tyrosine has been well studied in brain physiological and
pathological conditions (138). In a mouse GVHD model, the
metabolic profiles in recipient mice have been determined (139).
The low concentration of tyrosine in the gut was observed in
GVHD mice, and the tyrosine derived metabolites were
decreased in the mice that has less Blautia and Enterococcus.Frontiers in Immunology | www.frontiersin.org 8Dietary supplementation of tyrosine ameliorated GVHD and
restored the microbial diversity. In GVHD patients, the
metabolite markers in the serum have been investigated (140).
Alteration of tyrosine derived metabolites, such as p-cresol
sulfate and 3-phenylpropionate, were identified. Also, lysine
and phenylalanine were suggested as the altered metabolites.
To elucidate the importance of these metabolites, further
research is necessary.
Choline Derived Metabolites
Choline derived trimethylamine N-oxide (TMAO) results from
oxidation by hepatic flavin monooxygenases of trimethylamine
(TMA) that is a microbial metabolite of choline and other
choline containing compounds in the diet (141). TMAO is well
known to play a role in the initiation of atherosclerosis and
thrombosis in vascular inflammation and endothelial function
(142). TMAO and choline induced the GVHD progression in a
murine GVHD model (143). TMAO and choline induces M1
macrophages and M1-like cytokines in tissues and bone marrow
via NLRP3. TMAO are produced by the wide range of bacteria,
Anaerococcus hydrogenalis, Clostridium asparagiforme,
Clostridium hathewayi, Clostridium sporogenes (144).
Riboflavin (Vitamin B2) Derived
Metabolites
Riboflavin derived metabolites are also known to have an
important role in the GVHD pathogenesis. Various bacteria
including E. coli, Staphylococcus aureus and Pseudomonas
aeruginosa, produce these metabolites (145). These metabolites
expand the numbers of mucosal associated invariant T-cells
(MAIT) (146). Vitamin B2/B9 derived metabolites are
presented by MR1, the MHC class I-like molecule, to MAIT
cells producing IFN-g, IL-17 and antibacterial products. In
mouse and human GVHD, studies involving riboflavin derived
metabolites and GVHD have been accumulating, but there is still
no direct evidence that the riboflavin concentration in feces has a
direct impact on HSCT complications and outcomes (147–150).
In cord blood transplantation, microbial expression of enzymes
in the riboflavin synthesis pathway was associated with greater
MAIT reconstitution after HSCT (151).
Polyamines
Polyamines are polycationic molecules found in the
gastrointestinal tract and are produced by microbial
metabolism. They have various biological functions, including
IEC barrier function, innate immunity, pro-inflammatory
cytokines, and adaptive immunity (152). Spermine, a
polyamine, preserves TGF-b and IL-10 production by
inhibiting pro-inflammatory cytokine production in activated
macrophages (153). Moreover, the amino acid arginine is
metabolized to produce polyamines and decreases the
production of pro-inflammatory cytokines when administered
with bifidobacterial LKM512 (154). The oral supplementation of
spermine or spermidine promoted intraepithelial CD8+ T-cell
maturation and CD4+ T-cell increase in the lamina propria and B
cell increase in the rat spleen (155). However, the effects of
polyamines on GVHD have not yet been well studied. The oralAugust 2021 | Volume 12 | Article 703298
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and mucositis in allo-HSCT settings (156, 157). During allo-
HSCT, oral microbiota derived metabolites are altered in patients
with severe oral mucositis, and reduction of N-acetylputrescine
and agmatine, metabolites involved in the polyamine pathway,
were reported from salivary metabolic analysis in patients (158).
Fecal Microbiota Transplant
Alterations in intestinal microbiota composition and its
contribution to allo-HSCT outcomes have been studied to
determine the role of the intestinal microbiota in acute GVHD
severity. The strategy of manipulating or improving dysbiosis
post allo-HSCT via fecal microbiota transplant (FMT) were
introduced in the HSCT field because FMT treatment for
Clostridium difficile infection in non-HSCT settings has been
successfully reported (159). Recently, the utility of FMT in
patients with refractory GVHD after allo-HSCT has also been
reported (160). After FMT treatment, dysbiosis improvement
was observed as evidenced by increased beneficial bacteria and
resolution of clinical symptoms (161). The effects of FMT from
third parties were also assessed in a pilot study, and the feasibility
and effects on microbiome diversity in recipients have been
reported (162). An increase of Clostridiales abundance was
correlated with a significant increase of 3-IS concentration in
the urine in this study. In a randomized trial involving
autologous FMT early after allo-HSCT without broad-
spectrum antibiotics, the expansion and reestablishment of gut
microbiota diversity in autologous FMT recipients was reported
(163). Although only a limited number of studies regarding FMT
and GVHD treatment have been conducted, they have reported
similar results (164). FMT products were freshly processed or
frozen until subsequent use. The routes of administration mainly
include oral in packed capsules, nasogastric/nasoduodenal tubes,
or enema. Most FMT recipients were treated using third-line or
more therapies, whereas some received second-line therapy after
steroid failure. Complete response rate was high upon treatment
with second-line therapy. Responses to treatment were observed
within an average 14 days, with a median of two FMT
administrations. Changes in the stool microbiome were
analyzed using bacterial sequences. FMT recipients had
increased diversity and enrichment of Bacteroides ,
Lactobacillus, Bidifobacterium, and Faecalibacterium compared
with pre-FMTs (160). These changes were observed only when
anti-anaerobic systemic antibiotics were discontinued; however,
the fourth generation cephem did not affect the efficacy of FMT.
The gut microbiome comprises communities of bacteria,
fungi, and viruses that affect each other. Similar to bacterial
dysbiosis, alterations in the gut viral community are also
associated with gut GVHD (165). For instance, human herpes
virus 6 was detected in the serum, and picornavirus in the stool of
acute GVHD patients (166). The intestinal fungal composition
(mycobiome) after HSCT remains not well investigated. The
expansion of pathogenic Candida species was associated with a
substantial loss of bacterial diversity, especially that of anaerobes,
and increased the risk of fungal bloodstream infections (167).
There is a paucity of data regarding the changes in theFrontiers in Immunology | www.frontiersin.org 9mycobiome and virome in allo-HSCT post-FMT (168). In a
GVHD patient with repeated FMT treatments, longitudinal
studies observed dynamic changes in the microbiome,
mycobiome, and virome in the stool. In contrast to the
expansion of intestinal microbial composition post-FMT, the
gut mycobiome was first expanded and decreased after multiple
FMTs. The gut virome community varied substantially over time
with a stable increase in diversity. Furthermore, increased
microbial diversity post-FMTs was consistently reported;
however, the suggested mechanisms need to be elucidated,
including the changes in the microbial metabolites and the key
bacterial strains.
Overall, most studies have concluded that FMTs are generally
safe and effective for steroid-refractory GVHD patients.
However, infectious complications and deaths have been
reported, including death due to transmitted drug-resistant
bacteria from the FMT donor, bacteremia not from FMT
products, diarrhea due to norovirus in the FMTs, and other
infections, and were attributed to the immunocompromised
states of the patients. Importantly, critical complications
related to the recipient death have been reported, such as the
transmission of extended spectrum beta-lactamase producing
Escherichia coli that was proven using genomic sequencing from
FMT products (169). Before the clinical application of FMTs, the
preparation of FMT products should be standardized, and
universal stool banks are warranted (170). The precise practical
aspects of FMT treatments have been reviewed in detail
elsewhere (171).FUTURE PERSPECTIVES
The effects of dysbiosis post-HSCT on GVHD have been
investigated. Currently new studies on mycobiome and virome
in the intestine post-HSCT are focused because intestinal
environments were composed of various microorganisms other
than microbiota. As viruses and fungi are also part of the gut
microbiome, they are expected to provide a deeper
understanding of the connection between the microbiome and
GVHD. Microbial-derived metabolites, such as SCFAs and
indoles, play critical roles in promoting intestinal homeostasis
to overcome unwanted antibiotic influences and unfavorable
outcomes after HSCT. There are various targets that can affect
the results of HSCT, including microbial metabolites and specific
microbial strains that potentiate as prebiotics, probiotics, or FMT
in the clinical settings. All potential interventions are still under
investigation or not yet determined. However, the mechanisms
that cause dysbiosis post-HSCT, excluding broad-spectrum
antibiotics, remain elusive. Because IECs utilize oxygen for
energy, the intestinal environment has low oxygen levels (26,
89), resulting in the domination of anaerobic bacteria in the gut
microbiota. As shown in an inflammatory bowel disease model,
the metabolic change through PPAR-g signaling in IECs might
lead to dysbiosis in GVHD, which still require further
investigation (19). The role of SCFAs in cell metabolismAugust 2021 | Volume 12 | Article 703298
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intervening target cells without substantially affecting the
immune system (68, 172). Tolerance mediated by tissue
homeostasis reduces immunological damage from T-cells and
other cells. In addition, GVHD and GVL can also be separated.
Furthermore, the connection between GVL effects and dysbiosis
should be explored to identify potential strategies that boost
immune reactions.
Understanding the precise mechanisms and conditions in the
intestinal environment can promote the development of
prophylactic/therapeutic strategies targeting single or combined
modalities (such as FMT or FMT + butyrate, combinations of
metabolites) to reduce immunological reactions originating from
the gut (Figure 3). Furthermore, investigating the crosstalk
between local microbiota and injuries in target organs, such as
the lungs, could unveil other strategies to prevent HSCT-related
complications (173).Frontiers in Immunology | www.frontiersin.org 10AUTHOR CONTRIBUTIONS
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82. Rivera-Chávez F, Lopez CA, Bäumler AJ. Oxygen as a Driver of Gut
Dysbiosis. Free Radic Biol Med (2017) 105:93–101. doi: 10.1016/
j.freeradbiomed.2016.09.022
83. Spees AM, Wangdi T, Lopez CA, Kingsbury DD, Xavier MN, Winter SE,
et al. Streptomycin-Induced Inflammation Enhances Escherichia Coli Gut
Colonization Through Nitrate Respiration. mBio (2013) 4:e00430-13. doi:
10.1128/mBio.00430-13
84. Gillis CC, Hughes ER, Spiga L, Winter MG, Zhu W, Furtado de Carvalho T,
et al. Dysbiosis-Associated Change in Host Metabolism Generates Lactate to
Support Salmonella Growth. Cell Host Microbe (2018) 23:54–64.e6. doi:
10.1016/j.chom.2017.11.006
85. Reese AT, Cho EH, Klitzman B, Nichols SP, Wisniewski NA, Villa MM, et al.
Antibiotic-Induced Changes in the Microbiota Disrupt Redox Dynamics in
the Gut. Elife (2018) 7:e35987. doi: 10.7554/eLife.35987
86. Golob JL, DeMeules MM, Loeffelholz T, Quinn ZZ, Dame MK, Silvestri SS,
et al. Butyrogenic Bacteria After Acute Graft-Versus-Host Disease (GVHD)
are Associated With the Development of Steroid-Refractory GVHD. Blood
Adv (2019) 3:2866–9. doi: 10.1182/bloodadvances.2019000362
87. Vital M, Howe AC, Tiedje JM. Revealing the Bacterial Butyrate Synthesis
Pathways by Analyzing (Meta)Genomic Data. mBio (2014) 5:e00889. doi:
10.1128/mBio.00889-14
88. Clausen MR, Mortensen PB. Kinetic Studies on the Metabolism of Short-
Chain Fatty Acids and Glucose by Isolated Rat Colonocytes.
Gastroenterology (1994) 106:423–32. doi: 10.1016/0016-5085(94)90601-7
89. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte Metabolism Shapes the Gut
Microbiota. Science (2018) 362:eaat9076. doi: 10.1126/science.aat9076
90. Long C, Liu Y, He L, Tan Q, Yu Z, Xiao N, et al. Bacterial Lactase Genes
Diversity in Intestinal Mucosa of Mice With Dysbacterial Diarrhea Induced
by Antibiotics. 3 Biotech (2018) 8:176. doi: 10.1007/s13205-018-1191-5
91. Makarova K, Slesarev A, Wolf Y, Sorokin A, Mirkin B, Koonin E, et al.
Comparative Genomics of the Lactic Acid Bacteria. Proc Natl Acad Sci USA
(2006) 103:15611–6. doi: 10.1073/pnas.0607117103
92. Rhimi M, Aghajari N, Jaouadi B, Juy M, Boudebbouze S, Maguin E, et al.
Exploring the Acidotolerance of Beta-Galactosidase From Lactobacillus
Delbrueckii Subsp. Bulgaricus: An Attractive Enzyme for Lactose
Bioconversion. Res Microbiol (2009) 160:775–84. doi: 10.1016/j.resmic.
2009.09.004
93. Russo P, Arena MP, Fiocco D, Capozzi V, Drider D, Spano G. Lactobacillus
Plantarum With Broad Antifungal Activity: A Promising Approach to
Increase Safety and Shelf-Life of Cereal-Based Products. Int J Food
Microbiol (2017) 247:48–54. doi: 10.1016/j.ijfoodmicro.2016.04.027
94. Cabral ME, Abeijón Mukdsi MC, Medina de Figueroa RB, González SN.
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